Heterocyclic anticancer compounds: recent advances and the paradigm shift towards the use of nanomedicine's tool box
The majority of heterocycle compounds and typically common heterocycle fragments
present in most pharmaceuticals currently marketed, alongside with their intrinsic versatility …
present in most pharmaceuticals currently marketed, alongside with their intrinsic versatility …
Current development of cabazitaxel drug delivery systems
The second‐generation taxane cabazitaxel has been clinically approved for the treatment of
metastatic castration‐resistant prostate cancer after docetaxel failure. Compared with the …
metastatic castration‐resistant prostate cancer after docetaxel failure. Compared with the …
Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic …
M Eisenberger, AC Hardy-Bessard, CS Kim… - Journal of Clinical …, 2017 - ascopubs.org
Purpose Cabazitaxel 25 mg/m2 (C25) significantly improved overall survival (OS) versus
mitoxantrone (P<. 001) in postdocetaxel patients with metastatic castration-resistant prostate …
mitoxantrone (P<. 001) in postdocetaxel patients with metastatic castration-resistant prostate …
Enzyme-responsive polymeric micelles of cabazitaxel for prostate cancer targeted therapy
Cabazitaxel, a novel tubulin inhibitor with poor affinity for P-glycoprotein, is a second-
generation taxane holding great promise for the treatment of metastatic castration-resistant …
generation taxane holding great promise for the treatment of metastatic castration-resistant …
[BOOK][B] DeVita, Hellman, and Rosenberg's Cancer: Short Title
VT DeVita Jr, SA Rosenberg, TS Lawrence - 2022 - books.google.com
The standard-setting text in oncology for 40 years, DeVita, Hellman and Rosenberg's
Cancer: Principles and Practice of Oncology, 12th Edition, provides authoritative guidance …
Cancer: Principles and Practice of Oncology, 12th Edition, provides authoritative guidance …
New generation nanomedicines constructed from self-assembling small-molecule prodrugs alleviate cancer drug toxicity
H Wang, Z Lu, L Wang, T Guo, J Wu, J Wan, L Zhou… - Cancer research, 2017 - AACR
The therapeutic index for chemotherapeutic drugs is determined in part by systemic toxicity,
so strategies for dose intensification to improve efficacy must also address tolerability. In …
so strategies for dose intensification to improve efficacy must also address tolerability. In …
Co-delivery of IKBKE siRNA and cabazitaxel by hybrid nanocomplex inhibits invasiveness and growth of triple-negative breast cancer
IKBKE is an oncogene in triple-negative breast cancer (TNBC), and we demonstrate that
IKBKE small interfering RNA (siRNA) inhibits the proliferation, migration, and invasion of …
IKBKE small interfering RNA (siRNA) inhibits the proliferation, migration, and invasion of …
Sequencing of agents in castration-resistant prostate cancer
Until 2010, docetaxel was the only agent with proven survival benefit for castration-resistant
prostate cancer. The development of cabazitaxel, abiraterone acetate, enzalutamide, radium …
prostate cancer. The development of cabazitaxel, abiraterone acetate, enzalutamide, radium …
Castration-resistant prostate cancer: mechanisms, targets and treatment
Prostate cancer is the most common malignancy in men, and remains the second leading
cause of cancer-related death in this gender [1]. Data suggests that 10–20% of patients with …
cause of cancer-related death in this gender [1]. Data suggests that 10–20% of patients with …
Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer
G Galletti, BI Leach, L Lam, ST Tagawa - Cancer treatment reviews, 2017 - Elsevier
Patients with metastatic castration-resistant prostate cancer (mCPRC) now have an
unprecedented number of approved treatment options, including chemotherapies …
unprecedented number of approved treatment options, including chemotherapies …